Search research articles
Contact Us
Filters
Showing results (91-100 of 224) with videos related to
Page
of 23
Sort By:
JCO Oncology Practice
|
November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience
Ivan J Huang, Grace T Baek, Jonathan Cohen, et al.
European Journal of Haematology
|
January 19, 2022
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse
Rachel Hu, Wei Wei, Agrima Mian, et al.
Practical Radiation Oncology
|
October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
Aileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Haematologica
|
March 1, 2024
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: <i>post-hoc</i> analysis of a large clinical trial safety database
Jennifer R Brown, Paolo Ghia, Wojciech Jurczak, et al.
Plos One
|
December 3, 2014
Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model
Johnnie J Orozco, Ethan R Balkin, Ted A Gooley, et al.
Haematologica
|
July 1, 2024
<i>Erratum</i> to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
David W Woolston, Nathan D Lee, Mazyar Shadman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 12, 2021
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis
Stephen D Smith, Paolo Lopedote, Yazeed Samara, et al.
Blood Advances
|
April 9, 2025
The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy
Eleftheria Kampouri, Patrick Flaherty, Hu Xie, et al.
Blood Advances
|
June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas
Christina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse
Anjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Page
of 23
Search research articles
Search
Showing results (91-100 of 224) with videos related to
Sort By:
Page
of 23
JCO Oncology Practice
|
November 18, 2024
Clinical Relevance of Intensive Laboratory Monitoring With Standard Venetoclax Ramp-Up for Chronic Lymphocytic Leukemia: A Real-World Experience
Ivan J Huang, Grace T Baek, Jonathan Cohen, et al.
European Journal of Haematology
|
January 19, 2022
Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia at first relapse
Rachel Hu, Wei Wei, Agrima Mian, et al.
Practical Radiation Oncology
|
October 5, 2019
Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma
Aileen Kim, Philip Stevenson, Ryan D Cassaday, et al.
Haematologica
|
March 1, 2024
Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: <i>post-hoc</i> analysis of a large clinical trial safety database
Jennifer R Brown, Paolo Ghia, Wojciech Jurczak, et al.
Plos One
|
December 3, 2014
Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model
Johnnie J Orozco, Ethan R Balkin, Ted A Gooley, et al.
Haematologica
|
July 1, 2024
<i>Erratum</i> to: Ultra-deep mutational landscape in chronic lymphocytic leukemia uncovers dynamics of resistance to targeted therapies
David W Woolston, Nathan D Lee, Mazyar Shadman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
January 12, 2021
Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis
Stephen D Smith, Paolo Lopedote, Yazeed Samara, et al.
Blood Advances
|
April 9, 2025
The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy
Eleftheria Kampouri, Patrick Flaherty, Hu Xie, et al.
Blood Advances
|
June 17, 2025
Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas
Christina Poh, Jenna M Voutsinas, Mazyar Shadman, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 16, 2010
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse
Anjali S Advani, Mazyar Shadman, Francis Ali-Osman, et al.
Page
of 23